Abstract
BackgroundApproved anti-PD-1/PD-L1 immunotherapy has demonstrated clinical benefits for breast cancer (BC) mostly in triple-negative breast cancer (TNBC) patients. Developing effective immunotherapies for breast cancer is slow in part due to...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
